News for Blueprint Medicines Corporation (0HOJ.L)

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PR NewswireNEW YORK, June 3, 2025 NEW YORK, June 3, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

This modification comes after Sanofi declared its intention to buy Blueprint Medicines Corporation (NASDAQ:BPMC).

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in contingent value rights.

We recently published a list of These 10 Stocks Blew Past Expectations.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be […]

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corpor

The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsJenna Cohen - Vice President,...

PR NewswireCAMBRIDGE, Mass., April 25, 2025 CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced

Blueprint Medicines (BPMC) will release its Q1 2025 financial results on May 1, 2025. The company will host a live conference call and webcast at 8:00 a

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders. Read why BPMC stock is a strong buy.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts.